Profit Margin (Quarterly) Chart

Historical Profit Margin (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -24.44%
March 31, 2026 -62.44%
December 31, 2025 7.44%
September 30, 2025 1.42%
June 30, 2025 7.84%
March 31, 2025 -37.17%
December 31, 2024 10.14%
September 30, 2024 -8.57%
June 30, 2024 -13.23%
March 31, 2024 -39.22%
December 31, 2023 -25.16%
September 30, 2023 -12.81%
June 30, 2023 -12.64%
March 31, 2023 -25.45%
December 31, 2022 5.19%
September 30, 2022 -28.32%
June 30, 2022 -26.75%
March 31, 2022 -11.02%
December 31, 2021 -36.74%
September 30, 2021 -44.51%
June 30, 2021 -13.66%
March 31, 2021 1.41%
December 31, 2020 7.82%
September 30, 2020 59.89%
June 30, 2020 -3.23%
Date Value
March 31, 2020 -109.4%
December 31, 2019 20.56%
September 30, 2019 -91.18%
June 30, 2019 -17.90%
March 31, 2019 92.21%
December 31, 2018
September 30, 2018 -23.41%
June 30, 2018 24.29%
March 31, 2018 -39.63%
December 31, 2017 -37.77%
September 30, 2017 -87.80%
June 30, 2017 21.64%
March 31, 2017 -82.11%
December 31, 2016 -105.3%
September 30, 2016 -79.20%
June 30, 2016 -94.54%
March 31, 2016 -102.6%
December 31, 2015 -146.3%
September 30, 2015 -147.3%
June 30, 2015 -189.6%
March 31, 2015 -197.9%
December 31, 2014 -499.1%
September 30, 2014 -556.0%
June 30, 2014 -388.8%
March 31, 2014 -166.1K%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Viatris, Inc. -3.16%
60 Degrees Pharmaceuticals, Inc. -1.09K%
ANI Pharmaceuticals, Inc. 8.65%
Corcept Therapeutics, Inc. 16.45%
Veru, Inc. --